Short Read Sequencing Market Report 2025

The short read sequencing market size has grown rapidly in recent years. It will grow from $6.66 billion in 2024 to $7.86 billion in 2025 at a compound annual growth rate (CAGR) of 18%. The growth in the historic period can be attributed to genomic research initiatives, increased prevalence of genetic disorders, pharmaceutical and biotech research, diagnostic applications, and declining sequencing costs.

The short read sequencing market size is expected to see rapid growth in the next few years. It will grow to $15.21 billion in 2029 at a compound annual growth rate (CAGR) of 17.9%. The growth in the forecast period can be attributed to precision medicine advancements, rapid growth in personalized genomics, expanding applications in agriculture, surge in microbiome research, and rising demand in emerging markets. Major trends in the forecast period include automation and high-throughput, cloud-based solutions, integration of AI and machine learning, portable sequencing technologies, long-read sequencing synergy.

The anticipated increase in the prevalence of genetic diseases is set to drive the growth of the short-read sequencing market in the foreseeable future. Genetic diseases arise from abnormalities or mutations in an individual's DNA or genes, leading to physical, developmental, or biochemical irregularities that can impact their health. Short-read sequencing is instrumental in the analysis of genomes for identifying disease-associated variants comprehensively. For instance, a report by RARE-X in June 2022 highlighted a total of 10,867 rare diseases, encompassing both genetic and non-genetic conditions. Therefore, the growing prevalence of genetic diseases is a key driver behind the expansion of the short-read sequencing market.

The increasing adoption of personalized medicine is a significant contributor to the anticipated growth of the short-read sequencing market. Personalized medicine customizes medical treatment based on an individual's unique genetic makeup, providing more effective and precise healthcare interventions. Short-read sequencing plays a pivotal role in identifying genetic variations influencing drug response, facilitating the development of personalized treatment plans. For example, data from the Personalized Medicine Coalition in January 2023 indicated that out of the 37 new molecular entities approved by the Food and Drug Administration's Center for Drug Evaluation and Research in 2022, approximately 34%, or 12 of them, are classified as personalized medicines. Hence, the increasing adoption of personalized medicine is poised to drive the short-read sequencing market.

Technological advancements emerge as a key trend gaining momentum in the short-read sequencing market. Major companies in this market are focusing on technological advancements to enhance observation capabilities and maintain their positions. In October 2022, Pacific Biosciences Inc., a US-based producer of highly accurate sequencing technologies, initiated external beta testing of the Onso sequencing system. This system was designed to offer precise data while remaining cost-effective, catering to the needs of oncology researchers for sensitive and specific targeted sequence analysis findings.

Major companies operating in the short-read sequencing market are concentrating on the development of cost-effective short-read sequencers, specifically production-scale sequencers, to efficiently serve their users. Production-scale sequencers are high-throughput DNA sequencing platforms designed for large-scale genomic analysis in fields such as genomics, agriculture, and clinical research. For instance, Illumina, a US-based biotechnology company, launched the NovaSeq X Series in October 2022. This new technology, comprising NovaSeq X and NovaSeq X Plus, features production-scale sequencers designed to advance genomic medicine, providing faster, more powerful, and sustainable sequencing. The NovaSeq X Plus, capable of sequencing over 20,000 whole genomes per year, accelerates genomic discovery and clinical insights, while also demonstrating Illumina's commitment to reducing waste and environmental impact.

In March 2023, QIAGEN N.V., a Germany-based provider of sample and assay technologies, including short-read sequencing, formed a partnership with Sophia Genetics SA. This collaboration aims to enhance next-generation sequencing (NGS) capabilities by integrating QIAGEN's QIAseq reagent technology with SOPHiA's DDM (Digital Data Management) platform, facilitating improved tumor analysis and somatic variant detection. Sophia Genetics SA is a Switzerland-based company specializing in medical software.

Major companies operating in the short read sequencing market include F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., GE HealthCare Technologies Inc., Cytiva Lifesciences, Eurofins Scientific SE, Agilent Technologies Inc., Beckman Coulter Inc., Illumina Inc., QIAGEN N.V., PerkinElmer Inc., BGI Genomics Co Ltd, MGI Tech Co. Ltd., GenScript Biotech Corporation., 10x Genomics Inc., Novogene Co. Ltd, Oxford Nanopore Technologies Ltd., Pacific Biosciences of California Inc., Macrogen Inc., Genewiz Inc., Zymo Research Corporation, GenapSys Inc., Fasteris SA, Paragon Genomics Inc., Nabsys Inc., GATC Biotech AG.

North America was the largest region in the Short Read Sequencing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short read sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the short read sequencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Short-read sequencing, also known as next-generation sequencing (NGS), is a high-throughput DNA sequencing technique that produces short fragments or reads of DNA sequences. It has revolutionized genomics by facilitating the rapid and cost-effective analysis of entire genomes and transcriptomes.

The primary product categories in short-read sequencing comprise instruments, consumables, and services. Short-read sequencing instruments are the platforms or machines employed to generate short DNA fragments for analysis, allowing for the identification of genetic variations, mutations, and gene expression levels. Various technologies, including next-generation sequencing and Sanger sequencing, are utilized in workflows such as pre-sequencing, sequencing, and data analysis. These applications find use in clinical investigation, oncology, reproductive health, consumer genomics, agri genomics, forensics, HLA typing, and immune system monitoring. End users of short-read sequencing encompass academic research, hospitals and clinics, clinical research, and pharmaceutical and biotechnology companies.

The short-read sequencing market research report is one of a series of new reports that provides short-read sequencing statistics, including short-read sequencing industry global market size, regional shares, competitors with a short-read sequencing market share, detailed short-read sequencing market segments, market trends, and opportunities, and any further data you may need to thrive in the short-read sequencing industry. This short-read sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The short-read sequencing market includes revenues earned by entities by providing short-read sequencing services such as sequencing services, bioinformatics, sample processing, sequencing runs, data generation, and analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The short-read sequencing market also consists of sales-related products such as sequencing instruments, reagents, and consumables. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.